Total nucleated cell dose in graft is a better prognostic factor for survival in pediatric patients transplanted with bone marrow compared to CD34 +, CD3 +, or total mononuclear cell count-Reference-Cited by-同舟云学术

Total nucleated cell dose in graft is a better prognostic factor for survival in pediatric patients transplanted with bone marrow compared to CD34 +, CD3 +, or total mononuclear cell count

Published:2021-10-25 Issue:1 Volume:37 Page:19-24
ISSN:0733-2459
Container-title:Journal of Clinical Apheresis
language:en
Short-container-title:J of Clinical Apheresis

Author:

Kupeli Serhan¹^ORCID,Inan Gul¹,Ozkan Ayse¹,Sezgin Gulay¹,Bayram Ibrahim¹,Tanyeli Atila¹

Affiliation:

1. Department of Pediatric Oncology and Pediatric Bone Marrow Transplantation Unit Cukurova University Faculty of Medicine Adana Turkey

Publisher

Wiley

Subject

Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jca.21946

Reference10 articles.

1. Infused total nucleated cell dose is a better predictor of transplant outcomes than CD34 + cell number in reduced-intensity mobilized peripheral blood allogeneic hematopoietic cell transplantation

2. Higher doses of CD34+ progenitors are associated with improved overall survival without increasing GVHD in reduced intensity conditioning allogeneic transplant recipients with clinically advanced disease

3. The impact of CD34+ cell dose on platelet engraftment in pediatric patients following unmanipulated haploidentical blood and marrow transplantation

4. Risk Factors for Transplant Outcomes in Children and Adolescents with Non-Malignant Diseases Following Allogeneic Hematopoietic Stem Cell Transplantation

5. High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Transplant for non-malignant disorders: an International Society for Cell & Gene Therapy Stem Cell Engineering Committee report on the role of alternative donors, stem cell sources and graft engineering;Cytotherapy;2023-05